`
`CIP2139
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`IPR2017-00807
`
`
`
`AFFIDAVIT OF UMA N. EVERETT
`
`CASE IPR2017-00807
`
`l.
`
`1, Uma N. Everett, am more than twenty—one years of age, am competent
`
`to present this affidavit, and have personal knowledge of the facts set forth herein.
`
`2.
`
`This affidavit is given in support of the Patent Owner Cipla Limited’s
`
`Motion for Pro Hac Vice Admission.
`
`3.
`
`I am a director at the law firm of Sterne, Kessler, Goldstein and Fox
`
`P.L.L.C.
`
`4.
`
`I have been an attorney for more than 15 years. I have been litigating
`
`patent cases for nearly 12 years.
`
`5.
`
`I am an active member in good standing of the Bar of the District of
`
`Columbia.
`
`6.
`
`I have never been suspended or disbarred from practice before any court
`
`or administrative body.
`
`7.
`
`No court or administrative body has ever denied my application for
`
`admission to practice before it.
`
`2
`
`
`
`AFFIDAVIT OF UMA N. EVERETT
`
`CASE IPR2017—00807
`
`8.
`
`No court or administrative body has ever imposed sanctions or
`
`contempt citations on me.
`
`9.
`
`I have read and will comply with the Office Patent Trial Practice Guide
`
`and the Board’s Rules of Practice for Trials set forth in part 42 of the CPR.
`
`10.
`
`I understand that I will be subject to the Office’s Rules of Professional
`
`Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and disciplinary jurisdiction under
`
`37 CPR. § 11.19(a).
`
`11.
`
`I have not applied to appear pro hac vice in any proceedings before the
`
`Office in the past three years.
`
`12.
`
`In connection with the present proceeding, I have reviewed in detail
`
`US. Patent No. 8,168,620 (“the ’620 patent”), which is the patent challenged in this
`
`proceeding. I have also reviewed Exhibits submitted by Petitioner in this proceeding,
`
`including Exhibits 1003 and 1004 (Declarations of Robert Schleimer and Maureen
`
`Donovan) and the references cited in the Petition for Inter Partes Review (Paper 2).
`
`13.
`
`I have extensive experience litigating patent cases in the chemical arts
`
`and am familiar with technological and scientific principles relevant to the ’620
`
`patent. I have represented the Patent Owner and exclusive licensee (Meda
`_ 2 _
`
`3
`
`
`
`AFFIDAVIT OF UMA N. EVERETT
`
`CASE IPR2017—00807
`
`Pharmaceuticals, Inc.) in district court litigation that has been ongoing since
`
`December 2014, and involves, inter alia, the ’620 patent. In that litigation, I deposed
`
`both of Argentum’s experts, Dr. Robert Schleimer and Dr. Maureen Donovan.
`
`14.
`
`I have reviewed in detail the Pleadings submitted in this case, such as
`
`the Petition for Inter Partes Review (Paper 2).
`
`15.
`
`I have engaged in strategic and substantive discussions regarding this
`
`proceeding with Dennies Varughese, Phann.D., who is the lead counsel for Patent
`
`Owner in this proceeding. Through my years of patent litigation experience, I am
`
`very familiar with the legal theories advanced in this case.
`
`16.
`
`Therefore, I have an established familiarity with the subject matter at
`
`issue in this proceeding.
`
`4
`
`
`
`AFFIDAVIT OF UMA N. EVERETT
`
`CASE IPR2017—00807
`
`17.
`
`I understand that IPR counsel for Petitioner has agreed not to oppose
`
`Petitioner’s motion for my pro hac vice admission in this proceeding.
`
`W61
`
`Uma N. Everett
`
`Sworn to and subscribed before me
`this
`day of May, 2017.
`
`X V
`. W
`
`Notary Public
`
`m“mama,” '
`f“ \. - "ti/"z
`‘g ‘ I ' . u o I h I .'
`,9 ’1'
`s °.o'
`"5’ '5
`I-xv‘“ " w
`5% em 5':
`ago-1449.:
`
`.5!
`V .5
`a. o
`‘ $5-
`l! '21") '
`03 s.
`.
`,9,”
`a L 7‘0; saws
`-q
`5
`
`a:
`
`3
`
`5'?"
`8:
`3%p...
`Q
`5&3
`2—3
`48> .
`23%
`E5
`i— 5'
`g
`
`5
`
`